InnoMedica is a Swiss pharmaceutical company specialized in drug development with an innovative nanotransport system that aims to improve patient therapy. InnoMedica’s nanocarriers pursue the goal of prolonging the circulation of the transported pharmaceutical agents in the bloodstream and releasing them at the designated location in the body with precision. InnoMedica thereby wants to address the challenge of an efficient biodistribution of active agents in the human body while improving efficacy and reducing side effects. First applications in oncology, neurology, and virology demonstrate the versatility of this nanotechnology. Translation risks in InnoMedica’s drugs are unusually low because InnoMedica does not develop new active substances, but instead equips clinically established medicines with a biological autopilot. At InnoMedica, experienced entrepreneurs and researchers work together in order to bring these drugs to patients as expediently as possible.
Our Technology
Delivery system with precise focus
The patent-protected drug-delivery system can be combined with a multitude of medical agents and fine-tuned according to specific requirements. This versatility enables its use in a multitude of applications.
All pipeline products are based on InnoMedica’s nanocarriers acting as a drug delivery system. The aim is to improve the distribution of the encapsulated active agents in the patient’s body. The nanocarriers are equipped with a biological autopilot intending to release the active agent at the desired tissue in the body.
In developing its medicines, InnoMedica focusses on the patient and his/her wish for improved health and quality of life. This means prioritizing patient benefits, as well as the real-world applicability of new drugs. Improved patient benefits primarily depend on an increase in therapeutic efficacy and a decrease in side effects. In order to reduce time to approval, InnoMedica builds its medicines on approved, best-in-class active substances.
